Ausgabe 3/2014
Inhalt (20 Artikel)
Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer
Tarek M. A. Abdel-Fatah, Christina Perry, Paul Moseley, Kerstie Johnson, Arvind Arora, Stephen Chan, Ian O Ellis, Srinivasan Madhusudan
Progesterone stimulates progenitor cells in normal human breast and breast cancer cells
Heidi N. Hilton, N. Santucci, A. Silvestri, S. Kantimm, L. I. Huschtscha, J. D. Graham, C. L. Clarke
Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis
Tinghong Ye, Xiawei Wei, Tao Yin, Yong Xia, Deliang Li, Bin Shao, Xuejiao Song, Sisi He, Min Luo, Xiang Gao, Zhiyao He, Can Luo, Ying Xiong, Ningyu Wang, Jun Zeng, Lifeng Zhao, Guobo Shen, Yongmei Xie, Luoting Yu, Yuquan Wei
Clinical significance of CYLD downregulation in breast cancer
Mitsuhiro Hayashi, Hirofumi Jono, Satoru Shinriki, Takuya Nakamura, Jianying Guo, Aiko Sueta, Mai Tomiguchi, Saori Fujiwara, Mutsuko Yamamoto-Ibusuki, Kei-ichi Murakami, Satoshi Yamashita, Yutaka Yamamoto, Jian-Dong Li, Hirotaka Iwase, Yukio Ando
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
J. Thaddeus Beck, Gabriel N. Hortobagyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Hope S. Rugo, Barbara Pistilli, Norikazu Masuda, Lowell Hart, Bohuslav Melichar, Shaker Dakhil, Matthias Geberth, Martina Nunzi, Daniel Y. C. Heng, Thomas Brechenmacher, Mona El-Hashimy, Shyanne Douma, Francois Ringeisen, Martine Piccart
The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients
L. M. van Roozendaal, R. J. Schipper, K. K. B. T. Van de Vijver, C. M. Haekens, M. B. I. Lobbes, V. C. G. Tjan-Heijnen, M. de Boer, M. L. Smidt
Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
N. G. L. Jager, H. Rosing, J. H. M. Schellens, S. C. Linn, J. H. Beijnen
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
Ann E. McCullough, Patrizia Dell’Orto, Monica M. Reinholz, Richard D. Gelber, Amylou C. Dueck, Leila Russo, Robert B. Jenkins, Stefania Andrighetto, Beiyun Chen, Christian Jackisch, Michael Untch, Edith A. Perez, Martine J. Piccart-Gebhart, Giuseppe Viale
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
Wolfgang Janni, Tomasz Sarosiek, Boguslawa Karaszewska, Joanna Pikiel, Elzbieta Staroslawska, Piotr Potemski, Christoph Salat, Etienne Brain, Christian Caglevic, Kathryn Briggs, Michelle DeSilvio, Luca Marini, Christos Papadimitriou
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
Eduardo Martínez de Dueñas, Ana Lluch Hernández, Ángel Guerrero Zotano, Ramón María Pérez Carrión, José Ignacio Chacón López-Muñiz, Silvia Antolín Novoa, Ángela López Rodríguez, José Alejandro Pérez Fidalgo, Jaime Ferrer Lozano, Octavio Burgués Gasión, Eva Carrasco Carrascal, Andrés Hernando Capilla, Isabel Blancas López-Barajas, Montserrat Muñoz Mateu, María Helena López de Ceballos Reyna, Amparo Oltra Ferrando, Noelia Martínez Jañez, Vicente Carañana Ballerini, Antonio Antón Torres, Gustavo Catalán, José Ángel García Sáenz, Salomón Menjón, Ana María González-Angulo
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers
Jennifer T. Loud, Gretchen L. Gierach, Timothy D. Veenstra, Roni T. Falk, Kathryn Nichols, Allison Guttmann, Xia Xu, Mark H. Greene, Mitchell H. Gail
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy
Michel G. Khouri, Whitney E. Hornsby, Niels Risum, Eric J. Velazquez, Samantha Thomas, Amy Lane, Jessica M. Scott, Graeme J. Koelwyn, James E. Herndon, John R. Mackey, Pamela S. Douglas, Lee W. Jones
Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors
Heidi S. Wirtz, Denise M. Boudreau, Julie R. Gralow, William E. Barlow, Shelly Gray, Erin J. A. Bowles, Diana S. M. Buist
Treatment and outcomes in diabetic breast cancer patients
Heather Taffet Gold, Nour Makarem, Joseph M. Nicholson, Niyati Parekh
Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?
Catherine E. Loveland-Jones, Karen Ruth, Elin R. Sigurdson, Brian L. Egleston, Marcia Boraas, Richard J. Bleicher
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
Joanne Kotsopoulos, Jan Lubinski, Pal Moller, Henry T. Lynch, Christian F. Singer, Charis Eng, Susan L. Neuhausen, Beth Karlan, Charmaine Kim-Sing, Tomasz Huzarski, Jacek Gronwald, Jeanna McCuaig, Leigha Senter, Nadine Tung, Parviz Ghadirian, Andrea Eisen, Dawna Gilchrist, Joanne L. Blum, Dana Zakalik, Tuya Pal, Ping Sun, Steven A. Narod
Long-term impact of the 70-gene signature on breast cancer outcome
C. A. Drukker, H. van Tinteren, M. K. Schmidt, E. J. Th. Rutgers, R. Bernards, M. J. van de Vijver, L. J. van’t Veer
Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines
Reece C. C. Lim, John T. Price, Jacqueline A. Wilce
Steroid hormone receptor expression in breast cancer stroma
Mary E. Booth, Andrew M. Hanby, Valerie Speirs
Estrogen receptor status of breast stromal cells
Kevin C. Knower, Ashwini L. Chand, Colin D. Clyne